Total pharma industry venture financing deals in Q2 2019 worth $2.72bn were announced in the US, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked a decrease of 20.03% over the previous quarter and a drop of 26.4% when compared with the last four-quarter average of $3.74bn.
The US held a 73% share of the global pharma industry venture financing deal value that totalled $3.72bn in Q2 2019.
In terms of deal activity, the US recorded 158 deals during Q2 2019, marking a drop of 10.2% over the previous quarter and a drop of 7.6% over the last four-quarter average.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe US pharma industry venture financing deals in Q2 2019: Top deals
The top five pharma industry venture financing deals accounted for 21.7% of the overall value during Q2 2019.
The combined value of the top five pharma industry venture financing deals stood at $591m, against the overall value of $2.72bn recorded for the quarter. The top announced pharma industry venture financing deal tracked by GlobalData in Q2 2019 was Aisling Capital, Boxer Capital, Longitude Capital Management Co, Malin Corporation, Novartis Pharma, Pentwater Capital Management, Perceptive Advisors and Vivo Capital’s $142m venture financing of Poseida Therapeutics.
In second place was the $125m venture financing of SpringWorks Therapeutics by ArrowMark Partners, Bain Capital, Boxer Capital, BVF Partners, GlaxoSmithKline, HBM Healthcare Investments, LifeArc, Orbimed Advisors, Perceptive Advisors, Pfizer Venture Investments, Samsara BioCapital and Surveyor Capital and in third place was EcoR1 Capital, F2 Ventures, Fidelity Management & Research, Gilead Sciences, SVB Leerink, Redmile Group, Samsara BioCapital and Invus Group’s $120m venture financing of AlloVir.
The $104m venture financing of Encoded Genomics by Alexandria Venture Investments, Altitude Life Science Ventures, ARCH Venture Partners, Boxer Capital, Illumina Ventures, Matrix Capital Management Company, Menlo Ventures, RTW Investments and Venrock and Blackstone Life Sciences, Longitude Capital Management Co and Qiming Venture Partners USA’s venture financing of Talaris Therapeutics for $100m held fourth and fifth positions, respectively.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.
